JP2005525315A5 - - Google Patents

Download PDF

Info

Publication number
JP2005525315A5
JP2005525315A5 JP2003560001A JP2003560001A JP2005525315A5 JP 2005525315 A5 JP2005525315 A5 JP 2005525315A5 JP 2003560001 A JP2003560001 A JP 2003560001A JP 2003560001 A JP2003560001 A JP 2003560001A JP 2005525315 A5 JP2005525315 A5 JP 2005525315A5
Authority
JP
Japan
Prior art keywords
moiety
compound
aryl
heteroaryl
heteroalicyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003560001A
Other languages
English (en)
Japanese (ja)
Other versions
JP4412586B2 (ja
JP2005525315A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/000390 external-priority patent/WO2003059898A2/en
Publication of JP2005525315A publication Critical patent/JP2005525315A/ja
Publication of JP2005525315A5 publication Critical patent/JP2005525315A5/ja
Application granted granted Critical
Publication of JP4412586B2 publication Critical patent/JP4412586B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003560001A 2002-01-08 2003-01-08 エポネマイシンおよびエポキソマイシン類似物およびそれらの用途 Expired - Fee Related JP4412586B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34671102P 2002-01-08 2002-01-08
US37301102P 2002-04-16 2002-04-16
PCT/US2003/000390 WO2003059898A2 (en) 2002-01-08 2003-01-08 Eponemycin and epoxomicin analogs and uses thereof

Publications (3)

Publication Number Publication Date
JP2005525315A JP2005525315A (ja) 2005-08-25
JP2005525315A5 true JP2005525315A5 (https=) 2006-02-23
JP4412586B2 JP4412586B2 (ja) 2010-02-10

Family

ID=26994981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003560001A Expired - Fee Related JP4412586B2 (ja) 2002-01-08 2003-01-08 エポネマイシンおよびエポキソマイシン類似物およびそれらの用途

Country Status (6)

Country Link
US (2) US7524883B2 (https=)
EP (1) EP1463719A2 (https=)
JP (1) JP4412586B2 (https=)
AU (1) AU2003219652A1 (https=)
TW (1) TW200412349A (https=)
WO (1) WO2003059898A2 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
US8129346B2 (en) 2004-04-15 2012-03-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
EP2030981B1 (en) 2004-05-10 2014-07-09 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
PT2260835E (pt) * 2004-12-07 2013-05-28 Onyx Therapeutics Inc Composição para inibição do proteassoma
US7468383B2 (en) * 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7998997B2 (en) * 2005-07-05 2011-08-16 Trustees Of Tufts College Inhibitors of fibroblast activation protein alpha
MY171061A (en) * 2005-11-09 2019-09-24 Onyx Therapeutics Inc Compounds for enzyme inhibition
US20070207144A1 (en) * 2006-02-16 2007-09-06 Lee Rubin Ubiquitin/proteasome inhibitors for the treatment of spinal muscular atrophy
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
US7642369B2 (en) * 2006-09-12 2010-01-05 University Of Kentucky Research Foundation Epoxyketone-based immunoproteasome inhibitors
EP2152252A4 (en) * 2006-11-13 2010-06-02 Univ Columbia SELECTIVE PROTEASOMIC INHIBITORS FOR THE TREATMENT OF DIABETES
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US20110118274A1 (en) * 2007-08-23 2011-05-19 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
KR20170125413A (ko) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
EA038941B1 (ru) * 2007-11-06 2021-11-12 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ
EP2088205A1 (en) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
EP2730579A1 (en) 2008-06-17 2014-05-14 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
CN101638414B (zh) * 2008-07-30 2014-01-08 江苏先声药物研究有限公司 肽硼酸及其酯类化合物、制备方法及其用途
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
BRPI1010974A2 (pt) 2009-05-22 2019-09-24 Exelixis Inc benzoxazepinas baseada em inibidores p13k/ m tor contra doenças proliferativas
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
AU2010341530B2 (en) 2009-12-22 2016-03-10 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
EP2542238B1 (en) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
MX2012011298A (es) 2010-03-31 2012-11-06 Millennium Pharm Inc Derivados del acido 1-amino-2-ciclopropiletilboronico.
NZ602872A (en) 2010-04-07 2014-05-30 Onyx Therapeutics Inc Crystalline peptide epoxyketone immunoproteasome inhibitor
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
WO2014072985A1 (en) * 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
MA39964A (fr) 2014-05-20 2015-11-26 Millennium Pharm Inc Inhibiteurs du protéasome contenant du bore destinés à être utilisés après une thérapie contre le cancer primaire
WO2016126572A2 (en) * 2015-02-02 2016-08-11 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
CN106588965A (zh) 2015-10-15 2017-04-26 北京大学 脲拟肽硼酸化合物及其药物组合物、制备方法和用途
HRP20240793T1 (hr) 2018-04-18 2024-09-13 Constellation Pharmaceuticals, Inc. Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN110540547A (zh) * 2018-05-28 2019-12-06 秦艳茹 一种肽硼酸酯类化合物的合成与用途
LT4003532T (lt) 2019-07-24 2024-11-11 Constellation Pharmaceuticals, Inc. 7-chlor-2- (4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamido kristalinės formos
WO2025092827A1 (zh) * 2023-10-30 2025-05-08 上海汇伦医药股份有限公司 一种环氧类化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912133A (en) 1988-03-07 1990-03-27 Bristol-Myers Company BU-3862T antitumor antibiotic
US5071957A (en) * 1989-08-04 1991-12-10 Bristol-Myers Company Antibiotic BU-4061T
US4990448A (en) * 1989-08-04 1991-02-05 Bristol-Myers Company Bu-4061T
JP3107326B2 (ja) 1992-04-13 2000-11-06 日本化薬株式会社 生理活性物質ｎｋ−０４０００ｐ、ｎｋ−０４０００ｑ、その製造法及びそれを有効成分として含有する除草剤
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
WO2002096933A1 (en) 2001-05-30 2002-12-05 Novartis Ag 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives
WO2003033506A1 (en) 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Aminoborane acid derivative and proteasome inhibitory drug containing the same

Similar Documents

Publication Publication Date Title
JP2005525315A5 (https=)
IL159773A0 (en) Taxol enhancer compounds
JP2006511534A5 (https=)
CA2494049A1 (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
KR20080068084A (ko) 씨씨-1065 유사체를 제조하기 위한 방법 및 화합물
JP2019512478A5 (https=)
JP2018516243A5 (https=)
JP2023512501A5 (https=)
JP2013505946A5 (https=)
US20110172199A1 (en) Platinum-n-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof
RU2011118055A (ru) Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
WO1988001622A1 (fr) Derives de mitomycine
JP2007515419A5 (https=)
RU2004128465A (ru) Ингибиторы фарнезилпротеинтрансферазы как противоопухолевые агенты
CA2411172C (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors
JP2005501121A5 (https=)
JP2003535890A5 (https=)
KR100869037B1 (ko) 치환된 아크릴로일 디스타마이신 유도체 및 알킬화제를 포함하는 항종양 조성물
CA2409664A1 (en) Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione
JP2025500404A5 (https=)
US7642229B2 (en) Pharmaceutical composition and a product which includes a substituted acryloyl distamycin derivative, an antimicrotubule agent and/or an antimetabolite
JP2024540402A5 (https=)
JP2003535874A5 (https=)
AU2001267553A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites
JP2019529563A5 (https=)